Personally, no matter what is popular on social media, I prefer to get and make my medical decisions from reputable research and texts
What remains covered (with PA) are the cardiovascular risk-reduction indication (for members with established CVD) and diabetes coverage (Ozempic/semaglutide for T2D, which is a distinct indication)
In the pivotal Phase 2 obesity trial (n=338, 48 weeks), the 12 mg arm achieved a mean body weight reduction of 24.2% versus 2.1% in the placebo group [1]
This is especially important with growth hormonerelated peptides and anything that affects the endocrine system
While the patient groups did not differ by sex, M/M were of slightly lower age relative to both HC and SA and, unsurprisingly, higher fractional exhaled nitric oxide (FeNO) and lower FEV 1 (% predicted) were observed across groups from HC to SA
(2020, March 10)